The approval was based on data from the phase 3 IMpower110 study that compared the efficacy and safety of atezolizumab monotherapy to platinum-based chemotherapy in PD-L1-selected, chemotherapy-naive patients with stage IV NSCLC without ALK or EGFR mutations.
The FDA has approved the combination of Opdivo plus Yervoy for the first-line treatment of adult patients with metastatic non-small cell lung cancer whose tumors express PD-L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.
The FDA has granted accelerated approval to capmatinib for the treatment of adults with metastatic NSCLC with a mutation that leads to MET exon 14 skipping.
The FDA has granted Breakthrough Therapy designation to mobocertinib (TAK-788; Takeda) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy.
The phase 3 trial evaluating cemiplimab as a potential first-line treatment in patients with locally advanced or metastatic non-small cell lung cancer was stopped early due to “highly significant improvement” in overall survival.
Results demonstrated that nivolumab plus ipilimumab met the primary end point of superior overall survival at a prespecified interim analysis vs chemotherapy alone.
The researchers noted that medical distancing for those with cancer could help prevent the spread of the virus in this highly vulnerable population.
Disease control with entrectinib was found to be active and durable in ROS1 fusion-positive NSCLC.
Long-term follow-up of the Radiation Therapy Oncology Group 0617 trial continues to support a 60-Gy radiation therapy dose as the standard of care.
Baseline high body mass index was associated with improved survival in patients with non-small cell lung cancer treated with atezolizumab.
